Patents by Inventor Patrice O. Yarbough
Patrice O. Yarbough has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7094406Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.Type: GrantFiled: May 7, 2001Date of Patent: August 22, 2006Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services and Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert W. Tam, Kirk E. Fry
-
Publication number: 20030143241Abstract: Antigen and antibody vaccine composition effective in preventing hepatitis E virus (HEV) infection are disclosed. The antigen composition includes a peptide corresponding to a carboxyl terminal end region of the capsid protein encoded by the second open reading frame 2 of the HEV genome. The composition is effective in preventing HEV infection after vaccination. The antibody composition contains an antibody effective to block HEV infection of human primary hepatocytes in culture.Type: ApplicationFiled: June 6, 2002Publication date: July 31, 2003Applicant: GeneLabs Technologies, Inc.Inventors: Gregory R. Reyes, Daniel W. Bradley, Jr-Shin Twu, Michael A. Purdy, Albert W. Tam, Krzysztof Z. Krawczynski, Patrice O. Yarbough
-
Publication number: 20030124510Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.Type: ApplicationFiled: May 7, 2001Publication date: July 3, 2003Applicant: The United States of America, The Secretary of the Department of Health and Human ServicesInventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert W. Tam, Kirk E. Fry
-
Patent number: 6455492Abstract: Antigen and antibody vaccine composition effective in preventing hepatitis E virus (HEV) infection are disclosed. The antigen composition includes peptides corresponding to carboxyl terminal end regions of the second and third open reasing frames of the HEV genome. The composition is effective in preventing HEV infection after vaccination. The antibody composition contains an antibody effective to block HEV infection of human primary hepatocytes in culture.Type: GrantFiled: April 20, 1992Date of Patent: September 24, 2002Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Daniel W. Bradley, Jr-Shin Twu, Michael A. Purdy, Albert W. Tam, Krzysztof Z. Krawczynski, Patrice O. Yarbough
-
Publication number: 20020107360Abstract: Antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV antigens and in particular, soluble species of the capsid protein encoded by the carboxy terminal region of HEV ORF2, are immunoreactive with sera from individuals infected with HEV. In one embodiment, these antigens may be produced by a baculovirus expression vector and form virus-like particles (VLPs). The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV. The antigens are also useful in vaccine compositions effective in methods for preventing HEV infection.Type: ApplicationFiled: May 29, 2001Publication date: August 8, 2002Applicant: Genelabs Technologies, Inc.Inventors: Thomas R. Fuerst, C. Patrick McAtee, Patrice O. Yarbough, Yi-Fan Zhang
-
Patent number: 6379891Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.Type: GrantFiled: April 19, 2000Date of Patent: April 30, 2002Assignees: The United States of America as represented by the Department of Health and Human Services, Genelabs Technologies, Inc.,Inventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert Tam, Kirk E. Fry
-
Patent number: 6291641Abstract: Antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV antigens and in particular, a soluble 62 kDa species of the capsid protein encoded by ORF2, are immunoreactive with sera from individuals infected with HEV. The 62K antigen may be produced by a baculovirus expression vector and forms virus-like particles (VLPs). The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV. The antigens are also useful in vaccine compositions effective in methods for preventing HEV infection.Type: GrantFiled: June 7, 1995Date of Patent: September 18, 2001Assignee: Genelabs Technologies, Inc.Inventors: Thomas R. Fuerst, C. Patrick McAtee, Patrice O. Yarbough, Yi-Fan Zhang
-
Patent number: 6229005Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.Type: GrantFiled: August 3, 1998Date of Patent: May 8, 2001Assignees: The United States of America as represented by the Department of Health and Human Services, Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert W. Tam, Kirk E. Fry
-
Patent number: 6214970Abstract: Antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV antigens and in particular, soluble species of the capsid protein encoded by the carboxy terminal region of HEV ORF2, are immunoreactive with sera from individuals infected with HEV. In one embodiment, these antigens may be produced by a baculovirus expression vector and form virus-like particles (VLPs). The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV. The antigens are also useful in vaccine compositions effective in methods for preventing HEV infection.Type: GrantFiled: October 13, 1995Date of Patent: April 10, 2001Assignee: Genelabs Technologies, Inc.Inventors: Thomas R. Fuerst, C. Patrick McAtee, Patrice O. Yarbough, Yi-Fan Zhang
-
Patent number: 6120988Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.Type: GrantFiled: June 7, 1995Date of Patent: September 19, 2000Assignees: Genelabs Technologies, Inc., The United States of AmericaInventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert Tam, Kirk E. Fry
-
Patent number: 5824649Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.Type: GrantFiled: June 7, 1995Date of Patent: October 20, 1998Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert Tam, Kirk E. Fry
-
Patent number: 5789559Abstract: Nucleic acid sequences derived from enterically transmitted nonA/nonB viral hepatitis agent (HEV) are disclosed. DNA sequences encoding specific epitopes within viral protein sequences that are reactive with sera of individuals infected with different strains of HEV are also disclosed. These DNA sequences and fragments thereof are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, for example by using specific amplification of virus-derived DNA sequences, as well as for producing viral proteins or polypeptides.Type: GrantFiled: July 25, 1994Date of Patent: August 4, 1998Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert Tam, Kirk E. Fry
-
Patent number: 5770689Abstract: An antigen composition hepatitis E virus (HEV) infection are disclosed. The antigen composition includes peptides corresponding to carboxyl terminal end regions of the second and third open reading frames of the HEV genome.Type: GrantFiled: June 7, 1995Date of Patent: June 23, 1998Assignees: Genelabs Technologies, Inc., The United States of America as represented by the Department of Health and Human ServicesInventors: Gregory R. Reyes, Daniel W. Bradley, Jr-Shin Twu, Michael A. Purdy, Albert W. Tam, Krzysztof Z. Krawczynski, Patrice O. Yarbough
-
Patent number: 5686239Abstract: Peptide antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV derived peptides and in particular, SG3, are immunoreactive with sera from individuals infected with HEV. The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV.Type: GrantFiled: May 9, 1994Date of Patent: November 11, 1997Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Albert W. Tam, Patrice O. Yarbough